Which hedge funds own XLO? XILIO THERAPEUTICS INC, Q2 2026 13F holders
9 of the hedge funds tracked by WhaleCreep disclosed a position in XLO (XILIO THERAPEUTICS INC) in their Q2 2026 13F filings, worth $15.0m in total. The largest holder by portfolio weight is Stonepine Capital Management, LLC at 1.6% of its book. 5 managers opened a new position this quarter: Orbimed Advisors LLC, Prelude Capital Management, LLC, Adage Capital Partners GP, L.L.C., Citadel Advisors LLC. 2 exited: Caligan Partners LP, Ghisallo Capital Management LLC.
9tracked managers holding
5opened this quarter
2exited this quarter
Which hedge funds hold XLO? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Stonepine Capital Management, LLC | Q2 2026 | 1.6% | $2.2m | 225,994 | 252% | added |
| Sio Capital Management, LLC | Q2 2026 | 0.3% | $1.5m | 152,464 | 0% | held |
| Orbimed Advisors LLC | Q2 2026 | 0.1% | $5.7m | 592,300 | – | new |
| Frazier Life Sciences Management, L.P. | Q2 2026 | 0.1% | $4.0m | 422,505 | 0% | held |
| Gsa Capital Partners LLP | Q2 2026 | 0.0% | $130.0k | 13,590 | -20% | reduced |
| Prelude Capital Management, LLC | Q2 2026 | 0.0% | $111.1k | 11,600 | – | new |
| Adage Capital Partners GP, L.L.C. | Q2 2026 | 0.0% | $1.1m | 111,541 | – | new |
| Citadel Advisors LLC | Q2 2026 | 0.0% | $248.6k | 25,950 | – | new |
| Two Sigma Investments, LP | Q2 2026 | 0.0% | $139.3k | 14,544 | – | new |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Caligan Partners LP | 0.7% | $943.0k |
| Ghisallo Capital Management LLC | 0.0% | $116.1k |
Held in a manager's last filing on record
These managers have not filed for the latest quarter; their last disclosure is dated.
| Manager | Last filing | Weight |
|---|---|---|
| renaissance | Q2 2026 | 0.0% |
How has hedge fund ownership of XLO changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 10 | $15.7m |
| Q1 2026 | 7 | $7.0m |
| Q4 2025 | 2 | $2.8m |
| Q3 2025 | 1 | $172.5k |
| Q2 2025 | 1 | $111.6k |
| Q1 2025 | 1 | $128.7k |
| Q4 2024 | 1 | $283.3k |
| Q3 2024 | 1 | $209.8k |
| Q2 2024 | 1 | $279.5k |
| Q1 2024 | 1 | $269.0k |
| Q4 2023 | 1 | $115.0k |
| Q3 2023 | 1 | $44.0k |
| Q2 2023 | 1 | $53.0k |
| Q1 2023 | 1 | $60.0k |
| Q4 2022 | 1 | $100.0k |
| Q3 2022 | 1 | $83.0k |
Counts every tracked manager that disclosed XLO in that quarter's filing, including managers that have since stopped filing.